30-year follow-up of personality and clinical status of patients with anxiety and depression in the Nottingham Study of Neurotic Disorder

30-year follow-up of personality and clinical status of patients with anxiety and depression in the Nottingham Study of Neurotic Disorder: an observational cohort study following a randomised trial

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN65727743

Enrollment

130

Registered

2014-09-11

Start date

2014-01-01

Completion date

Unknown

Last updated

2024-01-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Topic: Mental Health

Interventions

In the original trial the patients were randomised to one of three drug treatments (diazepam, dothiepin and placebo), cognitive behaviour therapy or self-help, and most of the patients (70%) maintaine

Study Entry : Registration only

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. On no active treatment at baseline 2. Satisfies diagnostic criteria for GAD, dysthymia or panic disorder 3. Target Gender: Male & Female The participants to the original trial (Tyrer et al, 1988) were: 1. Aged between 18 and 65 2. Seen in general practice psychiatric clinics 3. Following the diagnostic criteria of the then new American diagnostic classification (DSM-III)) had a diagnosis of dysthymia (formerly neurotic depression), generalised anxiety disorder or panic disorder 4. Were not on any form of therapy for mental disorder at the time of randomisation

Exclusion criteria

Exclusion criteria: Lack of informed consent

Design outcomes

Primary

Measure	Time frame
Comprehensive Psychopathological Rating Scale; Timepoint(s): baseline, 2, 4, 6, 10, 16, 32, 52, and 104 weeks, and follow-up at 5, 12 and 30 years	—

Secondary

Measure	Time frame
1. DSM diagnosis; Timepoint(s): baseline, 10, 16, 32, 52, and 104 weeks, and follow-up at 12 and 30 years 2. Hospital admission; Timepoint(s): baseline, 2, 4, 6, 10, 16, 32, 52, and 104 weeks, and follow-up at 5, 12 and 30 years 3. Hospital Anxiety and Depression Scale - Anxiety section; Timepoint(s): baseline, 2, 4, 6, 10, 16, 32, 52, and 104 weeks, and follow-up at 5, 12 and 30 years 4. Hospital Anxiety and Depression Scale - Depression Section; Timepoint(s): baseline, 2, 4, 6, 10, 16, 32, 52, and 104 weeks, and follow-up at 5, 12 and 30 years 5. Montgomery-Asberg Depression Rating Scale; Timepoint(s): baseline, 2, 4, 6, 10, 16, 32, 52, and 104 weeks, and follow-up at 5, 12 and 30 years 6. Neurotic Disorder Outcome Scale (NDOS); Timepoint(s): baseline, 5, 12 and 30 years personality status; Timepoint(s): baseline, 2 years, 12 and 30 years 7. Social Functioning Questionnaire; Timepoint(s): 12 and 30 years 8. Suicidal behaviour; Timepoint(s): baseline, 2, 4, 6, 10, 16, 32, 52, and 104 weeks, and follow-up at 5, 12 and 30 years	—

Measure

Time frame

1. DSM diagnosis; Timepoint(s): baseline, 10, 16, 32, 52, and 104 weeks, and follow-up at 12 and 30 years 2. Hospital admission; Timepoint(s): baseline, 2, 4, 6, 10, 16, 32, 52, and 104 weeks, and follow-up at 5, 12 and 30 years 3. Hospital Anxiety and Depression Scale - Anxiety section; Timepoint(s): baseline, 2, 4, 6, 10, 16, 32, 52, and 104 weeks, and follow-up at 5, 12 and 30 years 4. Hospital Anxiety and Depression Scale - Depression Section; Timepoint(s): baseline, 2, 4, 6, 10, 16, 32, 52, and 104 weeks, and follow-up at 5, 12 and 30 years 5. Montgomery-Asberg Depression Rating Scale; Timepoint(s): baseline, 2, 4, 6, 10, 16, 32, 52, and 104 weeks, and follow-up at 5, 12 and 30 years 6. Neurotic Disorder Outcome Scale (NDOS); Timepoint(s): baseline, 5, 12 and 30 years personality status; Timepoint(s): baseline, 2 years, 12 and 30 years 7. Social Functioning Questionnaire; Timepoint(s): 12 and 30 years 8. Suicidal behaviour; Timepoint(s): baseline, 2, 4, 6, 10, 16, 32, 52, and 104 weeks, and follow-up at 5, 12 and 30 years

—

Countries

England, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026